Table 2.

Randomized crossover, double-blind, and placebo-controlled trials investigating the oral effect administration of Allium sativum powder on lipid profile, inflammation, and cardiovascular indexes.

	Baseline effect			Carryover effect: drug-placebo vs. placebo-drug			Period effect: period 1 vs. period 2			Treatment effect: drug vs. placebo
	Est. (SE)	df	p	Est.(SE)	df	p	Est.(SE)	df	p	Est.(SE)	df	p
K	0.30 (0.06)	67	<0.001	−0.08 (0.10)	68	0.429	−0.06 (0.08)	67	0.479	−0.04 (0.08)	67	0.630
BUN	0.62 (0.06)	67	<0.001	−5.07 (2.44)	68	0.041	11.32 (2.22)	67	<0.001	0.52 (2.21)	67	0.814
Cr	0.05 (0.02)	66	0.018	−0.79 (0.75)	68	0.302	0.33 (0.28)	66	0.248	0.58 (0.28)	66	0.047
Ca	0.55 (0.08)	58	<0.001	0.19 (0.13)	68	0.134	−0.60 (0.08)	58	<0.001	0.02 (0.08)	58	0.857
Ph	0.74 (0.06)	67	<0.001	−0.43 (0.15)	68	0.007	−0.57 (0.17)	68	0.001	−0.30 (0.16)	67	0.068
Chol	0.93 (0.04)	67	<0.001	−4.44 (2.52)	68	0.082	−16.28 (2.72)	67	<0.001	−2.66 (2.71)	67	0.329
TG	0.88 (0.03)	67	<0.001	1.01 (5.44)	68	0.864	12.17 (7.62)	67	0.115	−16.21 (7.60)	67	0.037
Na	0.06 (0.06)	67	0.306	0.36 (0.64)	68	0.573	−0.26 (0.68)	67	0.708	−0.66 (0.49)	67	0.177
OXLDL	0.19 (0.05)	67	<0.001	−36.96 (61.83)	68	0.552	−66.85 (57.14)	67	0.246	−325.27 (44.35)	67	<0.001
TAC	0.49 (0.06)	67	<0.001	−0.15 (0.07)	68	0.043	0.09 (0.12)	67	0.461	0.21 (0.11)	66	0.077
HCY	0.63 (0.05)	67	<0.001	1.94 (1.29)	68	0.135	−2.05 (1.32)	67	0.127	−7.29 (1.33)	67	<0.001

k: kalium; BUN: blood urea nitrogen; Cr: creatinine; Ca: calcium; Ph: the power of hydrogen; Chol: cholesterol; TG: triglyceride; Na: natrium; OXLDL: oxidized low-density lipoprotein; TAC: total antioxidant capacity; HCY: homocysteine.